Agilon Health (AGL) Cash & Equivalents (2020 - 2026)

Agilon Health (AGL) has reported Cash & Equivalents for 7 consecutive years, with $140.0 million the latest figure, recorded in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $140.0 million, up 2.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $140.0 million (up 2.22% YoY), and the FY2025 annual result was $173.7 million, down 7.71% from the prior year.
• Cash & Equivalents was $140.0 million for Q1 2026 at Agilon Health, down from $173.7 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $1.0 billion in Q1 2022 and troughed at $107.6 million in Q4 2023.
• Average Cash & Equivalents over 5 years is $289.4 million, with a median of $171.7 million recorded in 2025.
• Year-over-year, Cash & Equivalents jumped 870.43% in 2022 and slumped 76.88% in 2023.
• Over 5 years, Cash & Equivalents stood at $465.3 million in 2022, then plunged by 76.88% to $107.6 million in 2023, then jumped by 74.98% to $188.2 million in 2024, then declined by 7.71% to $173.7 million in 2025, then decreased by 19.41% to $140.0 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $140.0 million in Q1 2026, $173.7 million in Q4 2025, and $171.7 million in Q3 2025.